Suppr超能文献

tau 病的治疗选择。

Treatment options for tauopathies.

机构信息

Department of Psychiatry, J.W. Goethe-University, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt, Germany,

出版信息

Curr Treat Options Neurol. 2012 Apr;14(2):126-36. doi: 10.1007/s11940-012-0168-7.

Abstract

To date, there are no approved and established pharmacologic treatment options for tauopathies, a very heterogenous group of neuropsychiatric diseases often leading to dementia and clinically diagnosed as atypical Parkinson syndromes. Among these so-called Parkinson plus syndromes are progressive supranuclear palsy (PSP), also referred to as Steele-Richardson-Olszewski syndrome; frontotemporal dementia (FTD); and corticobasal degeneration (CBD). Available treatment strategies are based mainly on small clinical trials, miscellaneous case reports, or small case-controlled studies. The results of these studies and conclusions about the efficacy of the medication used are often contradictory. Approved therapeutic agents for Alzheimer´s dementia, such as acetylcholinesterase inhibitors and memantine, have been used off-label to treat cognitive and behavioral symptoms in tauopathies, but the outcome has not been consistent. Therapeutic agents for the symptomatic treatment of Parkinson's disease (levodopa or dopamine agonists) are used for motor symptoms in tauopathies. For behavioral or psychopathological symptoms, treatment with antidepressants-especially selective serotonin reuptake inhibitors-could be helpful. Antipsychotics are often not well tolerated because of their adverse effects, which are pronounced in tauopathies; these drugs should be given very carefully because of an increased risk of cerebrovascular events. In addition to pharmacologic options, physical, occupational, or speech therapy can be applied to improve functional abilities. Each pharmacologic or nonpharmacologic intervention should be fitted to the specific symptoms of the individual patient, and decisions about the type and duration of treatment should be based on its efficacy for the individual and the patient's tolerance. Currently, no effective treatment is available that targets the cause of these diseases. Current research focuses on targeting tau protein pathology, including pathologic aggregation or phosphorylation; these approaches seem to be very promising.

摘要

迄今为止,尚无针对 tau 病的获批和既定药物治疗选择。tau 病是一组非常异质的神经精神疾病,通常导致痴呆,并被临床诊断为非典型帕金森综合征。在这些所谓的帕金森综合征中,包括进行性核上性麻痹(PSP),也称为 Steele-Richardson-Olszewski 综合征;额颞叶痴呆(FTD);皮质基底节变性(CBD)。现有的治疗策略主要基于小型临床试验、各种病例报告或小型病例对照研究。这些研究的结果和关于所使用药物疗效的结论往往相互矛盾。批准用于治疗阿尔茨海默病的治疗药物,如乙酰胆碱酯酶抑制剂和美金刚,已被用于非标签治疗 tau 病的认知和行为症状,但结果并不一致。用于治疗帕金森病(左旋多巴或多巴胺激动剂)的症状性治疗药物用于 tau 病的运动症状。对于行为或精神病理症状,抗抑郁药(尤其是选择性 5-羟色胺再摄取抑制剂)的治疗可能会有所帮助。由于不良反应明显,抗精神病药物通常不能很好耐受;由于 tau 病患者发生脑血管事件的风险增加,这些药物应非常谨慎地使用。除了药物选择外,物理、职业或言语治疗也可用于改善功能能力。每种药物或非药物干预措施都应根据个体患者的特定症状进行调整,并且关于治疗类型和持续时间的决策应基于其对个体的疗效和患者的耐受性。目前,尚无针对这些疾病病因的有效治疗方法。目前的研究集中在针对 tau 蛋白病理学,包括病理性聚集或磷酸化;这些方法似乎很有前途。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验